2seventy bio

Experts Susan Abu-Absi and Stephen Sofen discuss bioprocessing challenges, automation, AI, and innovations on GEN Live. They anticipate FDA discussions, Vertex's CRISPR cell therapy, and emerging technologies at BPI 2024. Predictions include AI revolutionizing bioprocessing, CDMOs' critical role, and Bioprocess 5.0 focusing more on patient impact.

FDA approved ABECMA for earlier treatment of relapsed/refractory multiple myeloma after two prior therapies, expanding its use beyond four lines. Similarly, CARVYKTI received FDA approval for patients after one prior therapy, marking it as the first BCMA-targeted therapy for early relapse treatment.

FDA approved expanded use of CAR T-cell therapies, ide-cel and cilta-cel, for earlier treatment of relapsed or refractory multiple myeloma. Ide-cel now treats after two prior therapies, showing a 51% risk reduction in disease progression. Cilta-cel is approved for patients after one prior therapy, reducing risk by 59%. Both have known safety profiles.